Khaled M. Elsayes

ORCID: 0000-0003-0184-0717
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease Diagnosis and Treatment
  • Adrenal and Paraganglionic Tumors
  • Radiomics and Machine Learning in Medical Imaging
  • MRI in cancer diagnosis
  • Renal cell carcinoma treatment
  • Cancer, Hypoxia, and Metabolism
  • Hormonal Regulation and Hypertension
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Radiology practices and education
  • Pancreatic and Hepatic Oncology Research
  • Pituitary Gland Disorders and Treatments
  • Gastrointestinal disorders and treatments
  • Liver Disease and Transplantation
  • Neuroendocrine Tumor Research Advances
  • Gallbladder and Bile Duct Disorders
  • Sarcoma Diagnosis and Treatment
  • Medical Imaging and Pathology Studies
  • Abdominal Trauma and Injuries
  • Ultrasound in Clinical Applications
  • Lymphoma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Ovarian cancer diagnosis and treatment
  • Intraperitoneal and Appendiceal Malignancies
  • Soft tissue tumor case studies

The University of Texas MD Anderson Cancer Center
2016-2025

Hospital Italiano de Buenos Aires
2025

Hospital of the University of Pennsylvania
2025

Mayo Clinic in Arizona
2017-2024

Menoufia University
2024

University of Missouri
2024

Vanderbilt University Medical Center
2024

National University College
2024

New York University
2024

University of Washington
2024

Background Management of immune-related adverse events (irAEs) is important as they cause treatment interruption or discontinuation, more often seen with combination immune checkpoint inhibitor (ICI) therapy. Here, we retrospectively evaluated the safety and effectiveness anti-interleukin-6 receptor (anti-IL-6R) therapy for irAEs. Methods We performed a retrospective multicenter study evaluating patients diagnosed de novo irAEs flare pre-existing autoimmune disease following ICI were treated...

10.1136/jitc-2023-006814 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2023-06-01

Computed tomographic (CT) enterography is an emerging alternative to traditional fluoroscopy for the assessment of disorders small bowel. The greatly improved spatial and temporal resolution provided by multidetector CT scanners, combined with good luminal distention negative oral contrast agents bowel wall visualization, have made main imaging modality not only investigating proved or suspected inflammatory disease but also detecting occult gastrointestinal tract bleeding, neoplasms,...

10.1148/rg.307105052 article EN Radiographics 2010-11-01

Purpose To evaluate a fully automated machine learning algorithm that uses pretherapeutic quantitative CT image features and clinical factors to predict hepatocellular carcinoma (HCC) response transcatheter arterial chemoembolization (TACE). Materials Methods Outcome information from 105 patients receiving first-line treatment with TACE was evaluated retrospectively. The primary endpoint time progression (TTP) based on follow-up radiologic criteria (modified Response Evaluation Criteria in...

10.1148/ryai.2019180021 article EN Radiology Artificial Intelligence 2019-09-01

Gallbladder polyps are seen on as many 7% of gallbladder ultrasonographic images. The differential diagnosis for a polypoid mass is wide and includes pseudotumors, well benign malignant tumors. Tumefactive sludge may be mistaken polyp. Pseudotumors include cholesterol polyps, adenomyomatosis, inflammatory they occur in that order frequency. most common tumors adenomas primary adenocarcinoma, respectively. Polyp size, shape, other ancillary imaging findings, such base, wall thickening,...

10.1148/rg.352140095 article EN Radiographics 2015-03-01

558 Background: Nivo/ipi is a standard of care first-line (1L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC) but its role in variant histology RCC (vhRCC) has not been fully defined. Methods: We report single-institution experience nivo/ipi to treat 55 vhRCC between Nov. 2017 and Feb. 2024 at MD Anderson Cancer Center. Tumor response was measured by blinded radiologists using RECIST v1.1. Descriptive statistics the Kaplan-Meier method were used. Results:...

10.1200/jco.2025.43.5_suppl.558 article EN Journal of Clinical Oncology 2025-02-10
Coming Soon ...